No Data
Insiders Were the Biggest Winners as Shandong Sanyuan Biotechnology Co.,Ltd.'s (SZSE:301206) Market Cap Grew by CN¥620m Last Week
Sanyuan Bio (301206.SZ): has repurchased a total of 0.80% of its shares.
On April 1, Gelonghui reported that Sanyuan Biotechnology (301206.SZ) announced that as of March 31, 2025, the company had repurchased a total of 1,625,700 shares of its own stock through a Share Buyback dedicated Account via centralized bidding Trade, accounting for 0.80% of the company's total share capital, with the highest Fill Price of 27.85 yuan/share and the lowest Fill Price of 23.70 yuan/share, and the total amount of transactions reached 41.4774 million yuan (excluding transaction fees).
Sanyuan Biological (301206.SZ): Has not yet systematically deployed DeepSeek.
On March 10, Gelonghui reported that Sanyuan Bio (301206.SZ) stated on the investor interaction platform that the company continues to pay attention to the latest developments in the AI field, encourages employees to personally use AI tools such as DeepSeek to improve work efficiency, but the company has not yet systematically deployed DeepSeek. Future introduction will depend on a comprehensive consideration of technical feasibility, safety compliance, and business needs.
Sanyuan Biology (301206.SZ): has repurchased 0.54% of its shares in total.
Gelonghui, March 3rd | Sanyuan Biotech (301206.SZ) announced that, as of February 28, 2025, the company has repurchased a total of 1,085,700 shares through the Share Buyback dedicated Account via centralized bidding, accounting for 0.54% of the company's total equity, with a highest Fill Price of 27.85 yuan/share and a lowest Fill Price of 23.70 yuan/share, with a total transaction amount of 27.4452 million yuan (excluding transaction fees).
Sanyuan Biological (301206.SZ): Has not yet integrated DeepSeek related technologies.
On February 27, Gelonghui reported that Sanyuan Bio (301206.SZ) stated on the investor interaction platform that the company has not yet integrated DeepSeek related technology, but will continue to pay attention to Industry development and technological innovation, assessing its potential value to the company's Business.
Sanyuan Biological (301206.SZ): Continuously investing in the research and production of tagatose, has obtained multiple independent intellectual property rights.
On February 20, Gelonghui reported that Sanyuan Biological (301206.SZ) stated on the investor interaction platform that the company has been continuously investing in the research and development and production of tagatose, having obtained multiple independent intellectual property rights, including the recently acquired invention patent for "a method of catalytically synthesizing tagatose enzymes at high temperatures and their applications." This technological breakthrough provides an innovative solution for the biological fermentation method of tagatose, further optimizing production efficiency.
